Other
Payments to Acquire Finance Receivables
Royalty Pharma Payments to Acquire Finance Receivables decreased by 38.3% to $452.37M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 42697.2%, from $1.06M to $452.37M. Over 4 years (FY 2021 to FY 2025), Payments to Acquire Finance Receivables shows a downward trend with a -6.2% CAGR.
Analysis
StatementIncome Statement
SectionOther
CategoryEfficiency
SignalContext dependent
VolatilityModerate
First reportedQ1 2018
Last reportedQ1 2026May 6, 2026
How to read this metric
An increase suggests the company is expanding its customer financing programs to drive sales, while a decrease may indicate a tightening of credit or a shift in sales strategy.
Detailed definition
Refers to cash outflows associated with the acquisition of financial assets, such as loans or lease receivables, from th...
Peer comparison
Standard for capital-intensive companies that offer vendor financing to customers.
Metric ID:
other_payments_to_acquire_finance_receivablesHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $180.67M | $1.34B | $171.73M | $85.00K | $175.01M | $1.32B | $250.24M | $601.71M | $60.45M | $451.13M | $1.00B | $86.08M | $728.63M | $1.19B | $496.42M | $1.06M | $1.11M | $961.87M | $733.69M | $452.37M |
| QoQ Change | — | +639.5% | -87.1% | -100.0% | >999% | +652.1% | -81.0% | +140.5% | -90.0% | +646.3% | +122.2% | -91.4% | +746.4% | +63.9% | -58.4% | -99.8% | +5.4% | >999% | -23.7% | -38.3% |
| YoY Change | — | — | — | — | -3.1% | -1.5% | +45.7% | >999% | -65.5% | -65.7% | +300.5% | -85.7% | >999% | +164.8% | -50.5% | -98.8% | -99.8% | -19.5% | +47.8% | >999% |
Range$85.00K – $1.34B
CAGR+21.3%
Avg YoY Growth>999%
Median YoY Growth-2.3%
Current Streak2 quarters decline
Payments to Acquire Finance Receivables at Other Companies
Frequently Asked Questions
- What is Royalty Pharma's payments to acquire finance receivables?
- Royalty Pharma (RPRX) reported payments to acquire finance receivables of $452.37M in Q1 2026.
- How has Royalty Pharma's payments to acquire finance receivables changed year-over-year?
- Royalty Pharma's payments to acquire finance receivables increased by 42697.2% year-over-year, from $1.06M to $452.37M.
- What is the long-term trend for Royalty Pharma's payments to acquire finance receivables?
- Over 4 years (2021 to 2025), Royalty Pharma's payments to acquire finance receivables has grown at a -6.2% compound annual growth rate (CAGR), from $2.19B to $1.70B.
- What does payments to acquire finance receivables mean?
- Cash used to purchase financial receivables or loan portfolios from other parties.